Osman Kupik

Dr. Osman Kupik


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
OKOsman Kupik
Osman Kupik
YMYavuz Metin
Yavuz Metin
GEGulnihal Eren
Gulnihal Eren
NMNurgul Orhan Metin
Nurgul Orhan Metin
MAMedeni ARPA
Medeni ARPA
PURPOSE We aimed to investigate whether there is a correlation between dual-energy spectral computed tomography (DESCT) and F-18-fluorodeoxyglucose positron emission tomography/ computed tomography (F-18-FDG PET/CT) parameters in primary tumor and metastatic lymph nodes in patients with newly diagnosed lung cancer. METHODS Primary tumor and metastatic lymph nodes of 68 patients diagnosed with lung cancer were evaluated retrospectively with F-18-FDG PET/CT and DESCT imaging. The histologic subtypes were adenocarcinoma (n=29), squamous cell carcinoma (SCC) (n=26), small cell lung cancer (SCLC) (n=11), and large cell neuroendocrine cancer (LCNEC) (n=2). In terms of PET parameters, SUVmax, SUVmean, SULmax, SULmean, SULpeak, and normalized SUL values were obtained for primary tumors and metastatic lymph nodes. In terms of DESCT parameters, maximum and mean iodine content (IC), normalized IC values, iodine enhancement (IE) and normalized IE values were calculated. RESULTS We found no correlation between DESCT and F-18-FDG PET/ CT parameters in primary tumors and metastatic lymph nodes. In addition, no correlation was found in the analysis performed in any of the histologic subgroups. In patients with a primary tumor <3 cm, there was a moderate negative correlation between the parameters SUVmax-ICmax (r=-0.456, p =0.043), SUVmean-ICmax (r=-0.464, p =0.039) SULmean-ICmax (r=-0.497, p =0.026), SUVmax-ICmean (r=-0.527, p =0.020), SULmean-ICmean (r=-0.499, p =0.025), and SULpeak-ICmean (r=-0.488, p =0.029). CONCLUSION We consider that DESCT and F-18-FDG PET/CT indicate different characteristics of the tumors and should not supersede each other.

23 March 2020 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
OKOsman Kupik
Osman Kupik
SASerkan Akin
Serkan Akin
MTMurat Tuncel
Murat Tuncel
GEGülnihan Eren
Gülnihan Eren
ATAlev Türker
Alev Türker
BEBelkis Erbaş
Belkis Erbaş
Objective: In patients with non-Hodgkin lymphoma (NHL), we investigated 18F FDG PET/computed tomography (CT) parameters, clinical findings, laboratory parameters, and bone marrow involvement (BMI) status for predictive methods in progression-free survival (PFS) and overall survival (OS), and whether 18F FDG PET/CT could take the place of bone marrow biopsy (BMB). Methods: The performance of 18F FDG PET/CT (BMPET) was evaluated. The prognostic value of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), stage, international prognostic index (IPI) score, IPI risk, lactate dehydrogenase (LDH), B2 microglobulin, Ki67 proliferation index, and the presence of BMI was evaluated for OS and PFS. Kaplan–Meier curves were drawn for each designated cutoff value, and 5-year PFS and 7-year OS were evaluated using log-rank analysis. Results: The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of BMPET and BMB to identify BMI were 69, 100, 86.1, 80, 100%, and 81.6, 100, 92.5, 89, 100%, respectively. The sensitivity, specificity, PPV, NPV, and accuracy of BMPET in patients with Ki67- proliferation index >25% were all 100%. BMPET, IPI risk, MTV, and LDH were found to be independent prognostic predictors for PFS, whereas BMPET, SUVmax, and MTV for OS. Five-year PFS analysis estimated as follows: BMPET (+) = 22%, BMPET (−) = 80%, LDH ≤ 437 (U/L) = 86%, LDH > 437 (U/L) = 51%, MTV ≤ 56 (cm3) = 87%, MTV > 56 (cm3) = 49%, low IPI risk = 87%, intermediate IPI risk = 69%, high IPI risk = 25%. Seven-year OS analysis was found as: SUVmax ≤ 17.6 = 80%, SUVmax > 17.6 = 48%, MTV ≤ 56 (cm3) = 84.4%, MTV > 56 (cm3) = 45.8%, BMPET (−) = 72.5%, BMPET (+) = 42%. Conclusion: In the Ki-67 proliferation index > 25% group, 18F FDG PET/CT was able to differentiate BMI independently from NHL subgroups. We recommend using this method with large patient groups. MTV and BMPET were independent prognostic indicators for OS and PFS and may help to determine high-risk patients.

1 June 2023 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
OKOsman Kupik
Osman Kupik
MTMurat Tuncel
Murat Tuncel
PKPınar Özgen Kıratlı
Pınar Özgen Kıratlı
MAMeltem Gülsün Akpınar
Meltem Gülsün Akpınar
KAKadri Altundag
Kadri Altundag
BEBelkıs Erbaş
Belkıs Erbaş
This prospective study was planned to compare the predictive value of dynamic 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in locally advanced breast cancer patients (LABC) receiving neoadjuvant chemotherapy (NAC). Twenty seven patients with LABC [median age: 47, (26-66)] underwent a dynamic 18F-FDG PET study at baseline, and after 2-3 cycles of (NAC) were included (interim). Maximum standardized uptake value (SUVmax) values and SUV ratios for the 2nd, 5th, 10th, and 30th minutes and dynamic curve slope (SL) values and SL ratios were measured using 18F-FDG dynamic data. In addition, the values of SUVmean (2minSUVmean), SULpeak (2minSULpeak), metabolic volume (2minVol), and total lesion glycolysis (2minTLG) were measured for the first 2 min. Percent changes between baseline and interim studies were calculated and compared with the pathological results as the pathological complete response (PCR) or the pathological non-complete response (non-PCR). Receiver operating characteristic curves were obtained to calculate the area under the curve to predict PCR. Optimal threshold values were calculated to discriminate between PCR and non-PCR groups. Baseline study SUV 30 (p=0.044), SUV 30/2 (p=0.041), SUV 30/5 (p=0.049), SUV 30/10 (p=0.021), SL 30/2 (p=0.029) and SL 30/5 (p=0.027) values were statistically significant different between PCR and non-PCR groups. The percentage changes of 2minVol between PCR and non-PCR groups were statistically significant. For the threshold value of -67.6% change in 2minVol, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 87.2%, 77.8%, 63.6%, 93.3%, and 80.7%, respectively (area under the curve: 0.826, p=0.009). Semiquantitative parameters for dynamic 18F-FDG PET can predict PCR. % changes in 2minVol can identify non-responding patients better than other parameters.


20 May 2022 in Medicine
Verified
Journal Article
Open access
GEGülnihan Eren
Gülnihan Eren
OKOsman Kupik
Osman Kupik
To investigate necrosis on pre-radiotherapy (RT) 18F-FDG PET/CT (PETNECROSİS) as a predictor of complete metabolic response (CMR) in patients with non-small cell lung cancer (NSCLC). We evaluated patients with inoperable stage I–III NSCLC who underwent pre- and post-radiotherapy 18F-FDG PET/CT. The relationship between CMR and PETNECROSIS, SUVmax, gross tumor volume calculated with 18F-FDG PET/CT (GTVPET-CT), tumor size, histology, metabolic tumor volume (MTV), and RT dose was assessed using logistic regression analysis. To evaluate necrosis on 18F FDG PET/CT, we drew a region of interest (ROI) in the area showing visually very low/or no fluorodeoxyglucose (FDG) uptake on PET images. If the SUVmax was lower than the blood pool SUVmax and showed significantly lower attenuation (10–30 Hounsfield units [HU]) from the surrounding tissue on non-intravenous contrast-enhanced low-dose correlative CT, we defined it as necrotic (PETNECROSİS). Fifty-three patients were included in this study. The mean age was 68.1 ± 9.8 years. Twenty-one patients had adenocarcinoma, and 32 had squamous cell carcinoma. All parameters were independent of histologic status. Multivariate logistic regression analysis showed that SUVmax ≤11.6 vs >11.6, (P = .003; OR, 7.670, 95CI%: 2.013–29.231) and PETNECROSİS absence/presence were independent predictors for CMR (P = .028, OR: 6.704, 95CI% 1.214–30.394). The necrosis on 18F FDG PET/CT and SUVmax > 11.6 could be an imaging marker for the complete metabolic response after definitive chemoradiotherapy or definitive RT alone in patients with NSCLC.

16 July 2021 in Research Square
Verified
Preprint
Open access
PDF file
GEGülnihan Eren
Gülnihan Eren
OKOsman Kupik
Osman Kupik
Purpose: To investigate necrosis on pre-radiotherapy (RT) 18F-FDG PET/CT (PETNECROSİS) is a predictor for complete metabolic response (CMR) in patients with non-small cell lung cancer (NSCLC).Methods: We studied patients with inoperable stage I-III NSCLC who underwent pre- and post-radiotherapy 18F-FDG PET/CT. The relationship between CMR and PETNECROSIS, SUVmax, gross tumor volume calculated with 18F-FDG PET/CT (GTVPET-CT), tumor size, histology, metabolic tumor volume (MTV), and RT dose was assessed using logistic regression analysis. To evaluate necrosis on 18F FDG PET/CT, we drew a region of interest (ROI) in the area showing visually very low/or no fluorodeoxyglucose (FDG) uptake on PET images. If the SUVmax was lower than the blood pool SUVmax and showed significantly lower attenuation [10 to 30 Hounsfield Units (HU)] from the surrounding tissue on non-intravenous contrast-enhanced low dose correlative CT, we defined it as necrotic (PETNECROSİS).Results: Fifty-three patients were included in the study. The mean age was 68.1±9.8 years. Twenty-one patients had adenocarcinoma, 32 had squamous cell carcinoma. All parameters were independent of histologic status. Multivariate logistic regression analysis showed that, SUVmax ≤11.6vs>11.6 (p=0.003, OR:7.670, 95CI%:2.013-29.231) and PETNECROSİS absence/presence were independent predictors for CMR (p=0.028, OR:6.704, 95CI%1.214-30.394).Conclusion: The necrosis on 18F FDG PET/CT and SUVmax>11.6 could be an imaging marker for the complete metabolic response after chemoradiotherapy or RT alone in patients with NSCLC.